Skip to main content

Tweets

Sandoz has announced FDA approval for their two interchangeable biosimilars of denosumab - Wyost (denosumab-bddz) and Jubbonti (denosumab-bddz) based on reference products Xgeva and Prolia https://t.co/5OmJHDYWmM https://t.co/iHsqlJ9wYl
Dr. John Cush @RheumNow ( View Tweet )
3 weeks 2 days ago
DESIR study: new onset SpA pts followed w/ Xrays x 10 yrs showed progression from nr-axSpA to r-axSpA was 5.8% (in 294 followed 10 yrs), best predicted by baseline SI bone marrow edema, (OR 6.2), male, Sxs >1.5 yr, ASDAS ≥2.1 & smoking (only in HLA-B27+). https://t.co/A3Qqy8Eeym https://t.co/1I4UFI4h92
Dr. John Cush @RheumNow ( View Tweet )
3 weeks 2 days ago
Lancet - Full Read Review of the Diagnosis and management of ANCA-associated vasculitis by Stone, et al https://t.co/dtXOU8GT8p https://t.co/OXxdE8REGA
Dr. John Cush @RheumNow ( View Tweet )
3 weeks 2 days ago
Sniffles & Arthritis (3.1.2024) Dr. Cush reviews the news and journal reports from the past week on RheumNow. Are these associations with infection, biomarkers and weather real or imaginary? Linked or luck? Causal or casual? You decide.... https://t.co/xqoaycXeIm https://t.co/zQdXoj680T
Dr. John Cush @RheumNow ( View Tweet )
3 weeks 2 days ago
Head to Toe, There’s No Place These Cells Won’t Go Biana Modilevsky, DO presents her poster at RWCS 2024. https://t.co/AEd0gk6THj https://t.co/3Rsv07WwA9
Dr. John Cush @RheumNow ( View Tweet )
3 weeks 3 days ago
Cross-sectional multicenter study of 500 ax-SpA pts on biologics found 25% w/ Irritable Bowel Syndrome (IBS) that was linked to being Female gender, unemployed, higher BASDAI & BASFI, multiple biologics, FM , anxiety, depression & lower physical activity. https://t.co/RSKVcXZwLt https://t.co/RGsw3fHr3H
Dr. John Cush @RheumNow ( View Tweet )
3 weeks 3 days ago
An assessment of screening for latent tuberculosis in patients initiating b/tsDMARD therapy found over 1 in 3 new b/tsDMARD users did not receive TB screening within recommended time window, as well as variation in screening between drug classes In AC&R https://t.co/MGsWNZCiPW https://t.co/QRFq1lqWt6
ACR_Journals @ACR_Journals ( View Tweet )
3 weeks 3 days ago
It's a whole new world regarding job/residency/fellowship INTERVIEWs - Whats your interview preference?

Dr. John Cush @RheumNow ( View Tweet )

3 weeks 3 days ago
Machine learning of 701 Anti-Synthetase (Anti-Jo1, -PL7, -PL12, -EJ) identifies 3 Endotypes,independent Ab specificity #1 (24%) w/ RP-ILD & high mortality #2 (14%) dermatomyositis, intermediate prognosis #3 (62%) arthritis & mechanics hands, good prognosis https://t.co/y9LMCfMIgN https://t.co/y0MbYlbbrV
Dr. John Cush @RheumNow ( View Tweet )
3 weeks 3 days ago
Many with PsA Fail to Achieve Minimal Disease Activity Despite the availability of numerous advanced therapies for PsA, there remains a substantial burden and unmet need for improved therapies, according to a newly published Canadian study https://t.co/OUb3bKo98v https://t.co/FDCBcdyIBm
Dr. John Cush @RheumNow ( View Tweet )
3 weeks 3 days ago
Polyarteritis Nodosa (PAN): Clinical Features and Outcomes A multinational study of PAN through the international GLOBAL-PAN network shows PAN to be a complex, multisystem disorder with a high risk of relapse and low risk of death (11% at 10 years). https://t.co/jNNATtKTxA https://t.co/j5o6qTL2zM
Dr. John Cush @RheumNow ( View Tweet )
3 weeks 3 days ago
Australian study shows self-reported difficulties w/ ambulation (limited<=1 km) had a higher risk of hip and spinal fractures (32% to 219% more)/ Included 239 000 adults >45 yrs https://t.co/5rIkDOK69u https://t.co/iJ8o0dlGlS
Dr. John Cush @RheumNow ( View Tweet )
3 weeks 3 days ago